| Literature DB >> 31092174 |
Rupinder K Dhamoon1, Harvinder Popli1, Madhu Gupta1.
Abstract
Onychomycosis accounts for 50% of all nail disease cases and is commonly caused by dermatophytes. It was primarily considered a cosmetic problem but has been garnering attention lately due to its persistent nature and difficult treatment with relapses. With prolonged treatment duration and high cost involved in treating onychomycosis, several attempts have been made in overcoming the rigid nail barrier. The conventional treatment of onychomycosis involves oral and topical therapy. The oral antifungal agents though quite effective, are hepato-toxic and cause drug-drug interactions. Topical therapy is more patient compliant being devoid of such adverse effects but it suffers from another setback of improper nail penetration. Amorolfine and ciclopirox nail lacquers are popular market products. Since decades, efforts have been made to enhance topical delivery for efficiently treating onychomycosis. Mechanical, physical and chemical methods have been employed. Despite all the attempts made, the nail delivery issues are far from being solved. Recently, the focus has shifted to novel drug delivery systems like nanoparticles, microemulsions, polymeric films and nail lacquers for enhanced drug permeation and localized therapy. The research around the world is exploring their potential as effective treatment options. This review intends to further explore the novel delivery strategies to treat a persistent fungal infection like onychomycosis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Nail barrier; drug delivery; nanoparticles; novel strategies; onychomycosis; persistent infection.
Mesh:
Substances:
Year: 2019 PMID: 31092174 PMCID: PMC6691844 DOI: 10.2174/2211738507666190228104031
Source DB: PubMed Journal: Pharm Nanotechnol ISSN: 2211-7385
Current therapy available for onychomycosis.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Oral | Terbinafine | 250 mg per day for 6 weeks (fingernails) and | More effective, less relapses, safer for diabetic patients | Hepatotoxicity, less effective in non- dermatophyte onychomycosis, affects taste and smell, toxic dermal necrolysis | Impedes metabolism of tricyclicAntidepressants, beta blockers selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, should be avoided in breast- feeding mothers. | [ |
| Oral | Itraconazole | 200 mg twice a day for 1 week or pulse treatment of 2 courses for fingernails and 3-4 courses for toenails alone or in combination with amorolfine | Wider spectrum of antifungal activity, more effective in mixed infections, better for Candida onychomycosis | Absorption issues, peripheral | Negative inotropic effects, prohibited in patients with congestive heart failure, drug- drug interations especially with warfarin- like and coumarin- like drugs, should be avoided by breast-feeding mothers. | [ |
| Topical | Amorolfine | Till the desired results are obtained | Lower minimum inhibitory concentration, better retention in nail plate | Cleaning and abrasion required prior to application, itching, redness, irritation | Not approved for treatment in North America. | [ |
| Topical | Ciclopirox | Till the desired results are obtained | Good nail permeability, less resistance development | Nail abrasion is absolutely necessary, complete removal of previous layer is required | Only used when less than half of the nail is affected or oral therapy is prohibited. | [ |
Penetration enhancing techniques for treating onychomycosis.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Mechanical | Nail avulsion | Complete separation of nail plate from other units, | Anesthesia followed by Surgical (physical removal) or chemical (application of urea ointment) | No side effects or long term complications. | Postoperative nail deformity, pain. | [ |
| Nail abrasion | Filing or debriment of nail plate so as to increase penetration of topical antifungal drug | Sanding of the nail plate with sandpaper number 150 or 180 attached to dermabrader device | Decreases the critical fungal mass and aids the penetration, better patient acceptability, no complications. | Better efficacy is obtained in combination with topical antifungal agents. Also requires expert help. | [ | |
| Chemical | Addition of penetration enhancing chemical compounds | Keratolytic agents, enzymes, organic solvents, thiols, mercaptans, hydrophobins | These are added in the topical formulation as penetration enhancers | Enhanced nail permeation, non- invasive, convenient. | Itching, irritation at the site of application. | [ |
| Physical | Iontophoresis | Comprises of two electrodes and a power source | Application of small electric current (0.5 mA.cm-2) to enhance penetration | Does not affect nail structure, affordable, patient compliant. | Inappropriate intensity of current, cutaneous side effects. | [ |
| Laser therapy | Includes Nd:YAG short pulse and Q switch 1064 nm and the diode 870, 930, | Avulsion/ abrasion of the nail plate followed by laser treatment at 5000W/cm2 power density or applying CO2 laser beam with daily topical antifungal drug | Bypasses systemic toxicity, non- invasive, no teratogenic risks, no photo- ablation. | Tissue damage, photoageing, too many parameters to be controlled for desired results, less specificity, less information, high cost. | [ | |
| Photodynamic | Employs a light source to excite the photo-sensitizer to create reactive oxygen species which destroys fungal structure | Delivered in combination with methyl-aminolevulinic acid (three sessions, with 15 days interval) or 5-aminolevulinic acid (once a week) | No relapses, no hepatotoxicity, no interactions with drugs. | Teratogenic risks, slight pain, restriction in exposure to direct sunlight or heat for at least 2 days, improper penetration (for which either urea is employed or microabrasion is done). | [ | |
| Ultrasound | Low frequency ultrasonic waves improve penetration by forming micropores in the nail structure | 400 and 600 kHz frequencies and duration of 120 seconds were found most efficient for application | Enhanced and controlled rate of penetration, no systemic side effects. | Complicated device, expert help necessary, costly. | [ |
Most recent research work done on novel drug delivery strategies for treating onychomycosis.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Nanoparticles | 2018 | Ketoconazole-encapsulated crosslinked fluorescent supramolecular nanoparticles | Ratiometric mixing, | The nanoparticles showed high encapsulation efficiency, appropriate fluorescence, sustained release and intradermal retention. | Less invasive, localized and controlled release, dodges systemic side effects, can be applied to other diseases as well. | [ |
| Nanoparticles | 2018 | tioconazole-loaded polymeric nanocapsules | Ultrafiltration-centrifugation, | 3 formulations- lacquer, nanocapsule and film were prepared and characterized, almost 100% encapsulation efficiency, were stable, consistent release profile, nail poration provided no leverage, localized therapy observed through Nile Red. | Prolonged release, efficient delivery, greater drug payload, greater penetration. | [ |
| Nanoparticles | 2017 | Voriconazole-loaded nanostructured lipid carriers | HPLC, hydration studies, nanoparticles characterization, stability studies, | Maximum penetration was obtained with Urea as enhancer, drug release was 78- 86%, formulations were stable, the release kinetics fitted Higuchi model. | Deeper nail penetration, controlled release. | [ |
| Nanoparticles | 2017 | tioconazole | Nanocapsule characterization, morphological analysis, Ultrafiltration-centrifugation, | Homogenous nanoparticles, Newtonian properties, release was bi- exponential, better antifungal activity against | A hydrating formulation so increases permeation easily, better efficacy and deeper nail permeation. | [ |
| Nanoparticles | 2016 | Terbinafine loaded nanobased spanlastic vesicular carriers (nanovesicles) | Ethanol injection method, | Entrapment efficiency was 8 to 80%, sonication reduce particle size, amorphous, particles were unilamellar and spherical, better drug retention, more drug distribution and deeper nail penetration. | Better drug release and nail penetration. | [ |
| Nanoparticles | 2016 | Ketoconazole loaded nanoemulgel with penetration enhancer | Ultra-performance liquid chromatography (UPLC), Aqueous titration, high-pressure homogenization (HPH), Stress-Stability Studies, Nanoparticle characterization, nanoemulgel evaluation studies, | Optimized mean droplet size range: 63- 126nm, No phase separation or flocculation occurred, non-Newtonian, pseudo-plastic nature, maximum drug release was approx. 98%, better antifungal activity than drug solution. | Less toxicity and irritant potential, kinetically stable, safe and effective. | [ |
| Spanlastic | 2017 | Terbinafine loaded spanlastics delivered through novel dosage forms- | Ethanol injection method, characterization studies, | Drug permeation was obtained in the order: | Greater efficacy, patient compliance, more coverage, no irritation. | [ |
| Nail lacquer | 2017 | Terbinafine delivery | Thin film hydration technique, quality by design (QbD) technique, liposomes characterization, | Drug permeation was more with liposome loaded nail lacquer than with simple nail lacquer, same antifungal activity as of drug solution, formulations passed all evaluation tests. | Enhanced permeation and more therapeutics efficacy. | [ |
| Nail lacquer | 2017 | Ciclopirox-Based Eudragit RLPO Nail Lacquer | Penetration enhancers screening, 33 full factorial design, Physicochemical characterization, | Endopeptidase enzyme was selected as penetration enhancer, better permeation than marketed lacquer, better drug diffusion. | Enhanced permeation, non- invasive, localized therapy. | [ |
| Nail lacquer | 2017 | Terbinafine in polyurethane nail lacquer | Quasi-pre-polymerization method, Fourier Transform Infrared Spectroscopy (FTIR), | Contact angle< 90°, no cytotoxicity, better adhesion, lower MIC value, better | Biocompatible lacquers, Better drug diffusion, hydrophilic nature, nail adhesion. | [ |
| Polymeric films | 2016 | Polymeric films as novel dosage form for onychomycosis | Carboxy methyl cellulose sodium salt (Sod CMC), Chitosan, 2-Hydroxy ethyl cellulose (HEC), (Hydroxy propyl)methyl cellulose (HPMC), Polyvinyl pyrrolidone (PVP), Propylene glycol (PPG) were the polymers used for making films, film characterization, irritation studies, microscopic studies, adhesive studies. | Dry and non-sticky films, no irritation, HEC and HPMC showed swelling, the polymeric films showed stability, flexibility, water resistance and adhesiveness. | Non- invasive, suitable for nail application. | [ |